SANTA CRUZ BIOTECHNOLOGY, INC.

AOS-1 (H-9): sc-398080



Proteolytic degradation by the ubiquitin (Ub) system is essential for normal cell cycle progression, cellular differentiation and stress responses. Proteins conjugated to Ub are marked for progressive degradation by the 26S Proteosome. AOS-1, also designated SUMO-1-activating enzyme or ubiquitin-like 1-activating enzyme E1A, belongs to the ubiquitin-activating E1 family of proteins and plays an important role in the first step of the UBL1 conjugation pathway. AOS-1, which is a dimeric enzyme, functions as a UBLI E1 ligase, mediating the ATP-dependent activation of UBL1. AOS-1 can bind with UBLE1A and UBLE1B to form a heterodimer which can bind UBL1.

REFERENCES

BACKGROUND

- 1. Desterro, J.M., et al. 1998. SUMO-1 modification of $I\kappa B\alpha$ inhibits NF κB activation. Mol. Cell 2: 233-239.
- Okuma, T., et al. 1999. *In vitro* SUMO-1 modification requires two enzymatic steps, E1 and E2. Biochem. Biophys. Res. Commun. 254: 693-698.
- Gong, L., et al. 1999. Molecular cloning and characterization of human AOS-1 and UBA2, components of the sentrin-activating enzyme complex. FEBS Lett. 448: 185-189.
- Desterro, J., et al. 1999. Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1. J. Biol. Chem. 274: 10618-10624.
- Engelhardt, O.G., et al. 2001. Interferon-induced antiviral Mx1 GTPase is associated with components of the SUMO-1 system and promyelocytic leukemia protein nuclear bodies. Exp. Cell Res. 271: 286-295.
- 6. Pichler, A., et al. 2004. The RanBP2 SUMO E3 ligase is neither HECT- nor RING-type. Nat. Struct. Mol. Biol. 11: 984-991.
- 7. Lois, L.M. and Lima, C.D. 2005. Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1. EMBO J. 24: 439-451.

CHROMOSOMAL LOCATION

Genetic locus: SAE1 (human) mapping to 19q13.32; Sae1 (mouse) mapping to 7 A2.

SOURCE

AOS-1 (H-9) is a mouse monoclonal antibody specific for an epitope mapping between amino acids 261-287 near the C-terminus of AOS-1 of human origin.

PRODUCT

Each vial contains 200 $\mu g~lgG_3$ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-398080 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% stabilizer protein).

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS

AOS-1 (H-9) is recommended for detection of AOS-1 of mouse, rat and human origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for AOS-1 siRNA (h): sc-60174, AOS-1 siRNA (m): sc-60175, AOS-1 shRNA Plasmid (h): sc-60174-SH, AOS-1 shRNA Plasmid (m): sc-60175-SH, AOS-1 shRNA (h) Lentiviral Particles: sc-60174-V and AOS-1 shRNA (m) Lentiviral Particles: sc-60175-V.

Molecular Weight of AOS-1: 38 kDa.

Positive Controls: SW480 cell lysate: sc-22190, A549 cell lysate: sc-2413 or HEK293 whole cell lysate: sc-45136.

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG κ BP-HRP: sc-516102 or m-lgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz MarkerTM Molecular Weight Standards: sc-2035, UltraCruz[®] Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use m-lgG κ BP-FITC: sc-516140 or m-lgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz[®] Mounting Medium: sc-24941 or UltraCruz[®] Hard-set Mounting Medium: sc-359850.

DATA





AOS-1 expression in MCF7 (A), T-47D (B), SW480 (C),

HeLa (D) and NIH/3T3 (E) whole cell lysates.

AOS-1 (H-9): sc-398080. Western blot analysis of AOS-1 expression in SW480 (**A**), HEK293 (**B**), A549 (**C**), PC-12 (**D**), Neuro-2A (**E**) and F9 (**F**) whole cell lysates.

SELECT PRODUCT CITATIONS

- 1. Mete, B., et al. 2022. Human immunodeficiency virus type 1 impairs sumoylation. Life Sci. Alliance 5: e202101103.
- Singhal, J., et al. 2022. Host SUMOylation pathway negatively regulates protective immune responses and promotes *Leishmania donovani* survival. Front. Cell. Infect. Microbiol. 12: 878136.

RESEARCH USE

For research use only, not for use in diagnostic procedures.